ArticleBiology of sex differences2026
No impact of sex or testosterone treatment on wheel running in a rat model of inflammatory bowel disease.
Article in Biology of sex differences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex differences in inflammatory bowel disease (IBD) have been reported in humans, and gonadal steroid hormones are implicated in these sex differences. Although pain is a primary complaint among IBD patients, and pain often does not correlate with colon pathology, most animal studies focus on physiological rather than behavioral measures of IBD severity. Thus, the present study determined whether the impact of colitis on global measures of well-being is greater in female than male rats, and whether testosterone ameliorates this impact in females.
methodsBlank capsules were implanted into gonadally intact adult females and males, and another group of females was implanted with testosterone-filled capsules. Three weeks later, trinitrobenzene sulphonic acid (TNBS) was administered intracolonically to induce colitis. Body weight and continuous, home cage wheel running were measured daily, before and for 10 days after colitis induction. Estrous cycle was monitored for 21 days in a subset of females. At the end of the study, serum testosterone and estradiol were determined, in addition to clitoral/preputial gland size.
resultsTNBS suppressed body weight and wheel running, which partially recovered within 10 days, with no group differences in magnitude or time course of these effects. Serum testosterone was elevated in testosterone-treated compared to control females and did not differ significantly from males, whereas serum estradiol was similar across groups. Testosterone suppressed females' estrous cycling and increased clitoral gland size. At the end of the study, serum estradiol was found to be correlated with suppression of body weight and wheel running during the previous 10 days.
conclusionsThese results do not support the hypothesis of sex differences in well-being after IBD induction, or that testosterone ameliorates IBD effects in females, but corroborate human and rodent data suggesting that estradiol is associated with IBD severity in both sexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.